We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 28 investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Podcast Radio (PR) is the Ofcom-licensed UK digital broadcast radio station showcasing podcasts 24/7 globally. It is currently broadcasting in Surrey, Manchester, London, and Glasgow. Podcasting is expected to become a $3.3 billion industry by 2025. PR aims to be a disruptor in this segment. PR got front-page coverage in the international edition of Radio World magazine and has onboarded US radio Disc Jockey (DJ) Gene Baxter. The company will use 15% of the investment to secure digital radio broadcast transmission in 5 more UK cities by the end of 2020, 15% to partner with applicants for new digital radio transmitters, 15% to create a PR-led UK marketing campaign supported by social media, 25% to recruit new staff members, 10% to develop its on-air content, 10% to develop its website and application, and 10% to build new business partnerships to drive the international expansion of the company.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £149,023
Capital Physio is one of the UK’s fastest growing providers of retail physiotherapy. Since inception in 2012, the group has opened 17 clinics as part of a highly scalable and growth driven business model.  
days to go: Expired investment: £6,210
Sudor is a purpose-built platform for fitness professionals and their clients. The company claims to provide the technology and tools to empower fitness professionals as they build their digital business. Its core vision is to disrupt YouTube's fitness section that isn't purpose-built for fitness, doesn’t support challenges, track progress, or allows for 1:1 classes etc. Sudor asserts that its platform is different. It allows trainers to earn from their first subscriber. Trainers can also upload on-demand videos, stream live classes or create challenges for their subscribers. Sudor stresses that this gives its business ultimate scalability. It aspires to dominate the digital fitness industry in the US that is set to be worth $15 billion by 2026. The company has raised £465,000 to date, won the NOAH London Startup of the Year, and signed over 200 trainers. The portal hosts over 20,000 users and has paid out over £160,000 to trainers. The company states it will use the investment to scale Sudor worldwide.
days to go: Expired investment: £274,488
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
days to go: Expired investment: £251,600
mi-Hub is an office space designed for migrant entrepreneurs. Their goal is to educate migrant entrepreneurs to help them develop successful businesses so they can create jobs and help local economies. The office space is equip with meeting rooms, training rooms and business support.
days to go: Expired investment: £107,280
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph